JPM26: What’s in a biopharma? CEO says Teva has the goods In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a leading generics drugmaker. | Under CEO Richard Francis, Teva has long bee...

#JPM26 #biopharma #Teva #TevaPharmaceuticals #RichardFrancis #innovativemedicines #generics #biopharmaidentity #PivottoGrowth #RoyaltyPharma #TEV408 #vitiligo #phase2bstudy #genericmedicines #schizophrenia #olanzapine #Uzedy #longactingmedication #biosimilars #biosimilarmarket
zurl.co/ErF5t

More than 580,000 bottles of Prazosin blood-pressure pills recalled over cancer-risk chemical You could say this recall has regulators seeing red. More than 580,000 bottles of the prescription blood pressure drug Prazosin Hydrochloride are being pulled from pharmacy shelves across the United…

FDA sounds the alarm—blood pressure drug pulled for potential cancer risk. #Prazosin #DrugRecall #TevaPharmaceuticals #FDA

Cold Chain Technologies proves sea freight safe for pharma shipments CCT, Kuehne+Nagel, and Teva transported temperature-sensitive pharmaceuticals by sea, keeping cargo safe despite delays.

Cold Chain Technologies (CCT) has proven that sea freight can be a safe, cost-effective, and sustainable alternative to air cargo for temperature-sensitive pharmaceutical shipments.

#ColdChainTechnologies #KuehneNagel #TevaPharmaceuticals #pharmacargo #pharmaceutical #seafreight

Cold Chain Technologies secures pharma cargo on sea route High-value pharma shipments stayed safe on Germany-to-Australia sea route using CCT’s Enshield thermal protection.

Cold Chain Technologies (CCT) has demonstrated that high-value, temperature-sensitive pharmaceutical shipments can successfully travel by sea, offering a cost-effective and sustainable alternative to air freight.

#ColdChainTechnologies #KuehneNagel #TevaPharmaceuticals #pharmacargo #Germany

FDA approves AJOVY for paediatric migraine prevention - PharmaTimes Teva’s CGRP therapy becomes first approved option for children and adolescent

#neurology #neurosciencetherapies #FDA #USA #AJOVY #fremanezumabvfrm #paediatricmigraine #paediatricmigraineprevention #Teva #CGRPtherapy #TevaPharmaceuticals #episodicmigraine #CGRPantagonist #paediatricepisodicmigraineprevention #Migraine #paediatricmigraine
pharmatimes.com/news/fda-app...

Take Action Now: Stop #AlligatorAlcatraz, #Boycott #TevaPharmaceuticals
This week, we are demanding the shutdown of #Alligator #Alcatraz, boycotting Teva Pharmaceuticals, and more. Via #TheNationMagazine

Teva Pharmaceutical’s branded drugs boost first quarter profit JERUSALEM (Reuters) - Teva Pharmaceutical Industries (NYSE:TEVA) reported a larger than expected rise in first-quarter profit, helped by strong sales gains for a trio of its branded drugs treating migraines, Huntington’s disease and schizophrenia. The world’s largest generic drugmaker, Teva is relying on these and other innovative drugs to drive growth and help it raise its operating margin by four points to 30% by 2027. "Two years ago, nobody thought Teva could do anything in innovation," chief executive Richard Francis told Reuters. "What we’re seeing now ... shows whether it’s the US, Europe or international markets, we’re really good at innovative R&D and innovative commercialization." Francis said generics remains a key pillar of its growth strategy and Teva plans a number of copycat launches along with biosimilars in the next two years. Teva said on Wednesday it earned 52 cents per diluted share, excluding one-time items, in the January-March quarter, up from 48 cents a share a year earlier. Revenue rose 2% to $3.89 billion. Analysts had forecast earnings of 46 cents per share ex-items for the Israel-based company on revenue of $3.99 billion, LSEG I/B/E/S data showed. Growth was led by a 39% rise in sales of Huntington’s disease drug Austedo, a 26% gain in migraine medicine Ajovy and a 156% jump in schizophrenia treatment Uzedy. Teva expects Austedo sales of $1.95-$2.05 billion in 2025, with Ajovy hitting around $600 million and Uzedy at $160 million. Overall, Teva sees 2025 revenue of $16.8-$17.4 billion, with adjusted earnings per share of $2.45-$2.65, up from a prior estimate of $2.35-$2.65. The company noted its net debt fell to $15 billion and that it expects net savings of $700 million by 2027. Francis said that Teva’s strong manufacturing footprint in the United States should enable it to avoid damage from potential U.S. tariffs. Teva’s New York listed shares rose 7.3% to $17.29 by late morning trade. "That ... reinforces our view that Teva is well-positioned for sustained multiple expansion," he said.

Click Subscribe #TevaPharmaceuticals #Pharmaceuticals #Biotech #Healthcare #Q1Profit

Teva's Ajovy shows positive results in preventing pediatric migraines - PharmaTimes Phase 3 trial indicates significant efficacy and safety for children and adolescents

#neurology #migraine #Teva #TevaPharmaceuticals #Ajovy #fremanezumab #paediatricmigraines #paediatricmigraineprevention #Phase3SPACEstudy #episodicmigraines #episodicmigraineprevention #chronicmigraine #migraine #SPACEtrial #paediatricpatients #CGRPpathwaytreatment
pharmatimes.com/news/tevas-a...